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ABSTRACT: The global sanitary crisis caused by the emergence of the
respiratory virus SARS-CoV-2 and the COVID-19 outbreak has revealed
the urgent need for rapid, accurate, and affordable diagnostic tests to
broadly and massively monitor the population in order to properly
manage and control the spread of the pandemic. Current diagnostic
techniques essentially rely on polymerase chain reaction (PCR) tests,
which provide the required sensitivity and specificity. However, its
relatively long time-to-result, including sample transport to a specialized
laboratory, delays massive detection. Rapid lateral flow tests (both
antigen and serological tests) are a remarkable alternative for rapid
point-of-care diagnostics, but they exhibit critical limitations as they do
not always achieve the required sensitivity for reliable diagnostics and
surveillance. Next-generation diagnostic tools capable of overcoming all
the above limitations are in demand, and optical biosensors are an excellent option to surpass such critical issues. Label-free
nanophotonic biosensors offer high sensitivity and operational robustness with an enormous potential for integration in compact
autonomous devices to be delivered out-of-the-lab at the point-of-care (POC). Taking the current COVID-19 pandemic as a critical
case scenario, we provide an overview of the diagnostic techniques for respiratory viruses and analyze how nanophotonic biosensors
can contribute to improving such diagnostics. We review the ongoing published work using this biosensor technology for intact virus
detection, nucleic acid detection or serological tests, and the key factors for bringing nanophotonic POC biosensors to accurate and
effective COVID-19 diagnosis on the short term.
KEYWORDS: point-of-care diagnostics, optical biosensors, nanoplasmonics, silicon photonics, virus detection, coronavirus, covid-19,
respiratory virus, label-free detection
Viral respiratory tract infections (RTI) are one of the leadingcauses of hospitalization in developed countries and a
common cause of death.1 In developing countries, the concern is
even greater due to the shortfall in healthcare (vaccines, efficient
diagnostics, clinical resources, etc.), nutrition, and hygienic
measures.2 Since the discovery of influenza in the early 1930s,
tens of common viruses have been identified, and in the past
decades, new emerging viruses have appeared with increasing
frequency, gradually warning the scientific and social commun-
ity toward improving identification, surveillance, and control to
prevent and stop them from causing epidemics. After the critical
outbreaks of SARS (Severe Acute Respiratory Syndrome) in
2003, H1N1 flu (swine flu) in 2009, and MERS (Middle East
Respiratory Syndrome) in 2012, it has been in 2019−2020 when
the world has been globally dealing with the most critical health
situation in years due to the SARS-CoV-2 (a coronavirus closely
related to MERS-CoV and SARS-CoV) causing the COVID-19
outbreak. COVID-19 has become a global pandemic in less than
four months since its appearance in late December 2019 in
Wuhan (China). In such a short period since the appearance of
the first suspicious cases and further confirmation, the virus has
massively spread worldwide, affecting all countries and
territories, leaving to date (July 2020) more than 14 million
infected people and nearly 600,000 deaths. The surprisingly fast
propagation of SARS-CoV-2 has been due to factors such as its
contact and airborne routes of transmission (i.e., transfer from
contaminated fomites to mouth, nose, and eyes, and also via
aerosols generated and remaining in suspension when sneezing,
coughing, breathing, and talking), its high infection rate, long
incubation period from exposure to onset of symptoms,
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contagious time (three-week period from onset of symptoms),
the variety of symptoms (fatigue, fever, cough, dyspnea···) and,
more importantly, the lack of symptomatology, which hinders a
rapid identification, facilitating its imperceptible spread. The
significance of this crisis has also sadly revealed the lack of global
readiness from governments, public organizations, and
communities to face and manage both the social and health
consequences of the outburst. The scientific community is now
globally challenged to provide solutions in three main areas: (1)
prevention, through the development of efficient vaccines that
provide immunity and protection to the population; (2)
therapeutics, through the development of specific drugs and
therapies to treat and cure the disease; and (3) diagnostics,
through the implementation of massive, affordable, and reliable
detection tests.
Once the emergence has been recognized and identified, it is
crucial to initiate actions to stop the virus transmission and
prevent the spread. Besides social distancing and confinement,
the strategy must also involve careful tracing and massive testing
of the community, which has dramatically revealed the need for
efficient, readily accessible diagnostics methods that specifically
confirm the presence of the virus as soon as possible. Given the
health and social emergency, mass-produced, reliable, and very
sensitive diagnostics to promptly identify the pathogen are then
mandatory and a paramount priority to improve patient
management, infection control, and more efficient epidemio-
logical studies.
In this review, we provide an overview of current and new
diagnostic strategies that can be implemented for SARS-CoV-2
detection. We mainly focus on label-free nanophotonic
biosensors as a potential technology for rapid and efficient
virus infection diagnostics. The main working principles and
characteristics of nanophotonic biosensors are briefly described
together with examples of their recent applications for
respiratory virus detection.
■ DIAGNOSTIC STRATEGIES FOR RESPIRATORY
VIRUS INFECTION
Viral culture has been for a long time the traditional gold
standard diagnostics technique for RTI, as it provides high
specificity, moderate sensitivity, and quantitative information.
However, it is time-consuming (5 to 20 days) and requires
experienced staff for results interpretation. Current diagnostic
methods for respiratory tract infections are divided into three
distinct approaches:3,4
(1) Detection of the viral genome through nucleic acid
amplification tests (NAATs), mainly polymerase chain
reaction (PCR) tests in its different variants;
(2) Direct detection and identification of the intact virus (or
fragments) through the recognition of viral antigens
(structural proteins of the virus);
(3) Indirect detection of antibodies produced by the infected
host during the course of the infection, known as
serological testing.
Strategies 1 and 2 usually require a nasopharyngeal sample
(nasal swabs), whose viral load is generally high, and they are
useful while the infection is active; whereas strategy 3 requires a
blood sample and it can only be applied from day 4 or 5 after the
infection.
Nucleic Acid Amplification Tests (NAATs).NAATs based
on PCR in its different variants (reverse-transcriptase PCR, RT-
PCR, real-time quantitative PCR, qPCR, etc.) for the
amplification and detection of specific sequences of the viral
nucleic acids, are currently well established in routine analysis
and indeed have drastically redefined the diagnostics protocol
and efficiency. The relatively fast access to the genomic sequence
of the pathogens, even in newly emerged viruses, such as the
SARS-CoV-2, enables the rapid design and production of highly
specific PCR kits for its ready and sensitive detection, and even
offering quantitative values of the viral load (typically between
100 and 1000 copies/mL). This has been evidenced with
COVID-19, when within the first months after the outbreak,
many PCR kits were commercialized and distributed, offering
excellent sensitivity and specificity, turning them into the gold
standard diagnostics technique for SARS-CoV-2 infection.
Although the analysis is relatively fast (i.e., less than 2 h), the
sample-to-result time can be considerably longer (i.e., from 4−6
h to a few days), mainly due to sample transportation and
treatments that must be performed in centralized laboratories.
The initial limitations of PCR techniques related to reduced
multiplexing capabilities have also improved significantly. Many
companies offer either detection kits for the three most common
respiratory viruses (influenza A/B and the respiratory syncytial
virus, RSV), or more sophisticated platforms which offer
cartridges for the detection of panels of 6, 12, or even 20
respiratory pathogens.5,6 In all cases, the performance of such
testing platforms renders sensitivity and specificity values
around 95−100% and could be adapted to include the novel
coronavirus.6 However, most of them are not compatible with
point-of-care testing, do not offer quantitative information, are
necessarily linked to their commercial instrument, and are
relatively costly.7
Current efforts are mostly directed to point-of-care (POC)
decentralization, to accelerate and promote the analysis outside
the lab, close to the sample collection,8 and already a couple of
them have received express authorization to be used for
qualitative detection of SARS-CoV-2, such as the Accula test
from Mesa Biotech Inc. or the ID Now test from Abbott
Diagnostics. The development in recent years of new NAAT-
based techniques that circumvent the use of thermocyclers,
required for up and down temperature cycles in PCR, have
boosted these new designs, easing the portability and eventually
the transfer into POC devices.9,10 This is the case, for instance,
of Loop-Mediated Isothermal Amplification (LAMP) or Rolling
Circle Amplification (RCA) techniques, which also rely onDNA
amplification, but are designed to operate at constant temper-
ature (60−65 or 37 °C, respectively).11−14 Both have been
implemented for the detection of several pathogens, including
viruses such SARS-CoV,15,16 H5 avian influenza virus,17 and also
SARS-CoV-2.18 Besides, microarray-based methods, enabling
multiplexed assays and with a high potential for POC testing,
have been designed and applied for different virus detection
(influenza, RSV, generic CoV, MERS-CoV, etc.).19,20 Finally,
CRISPR-based techniques are also emerging as novel diagnostic
tools, using the RNA-targeting Cas13 enzyme for highly specific
pathogen detection, which is being intensively studied and
applied as well for COVID-19 diagnostics.21−23
Antigen-Directed Virus Detection. Antigen-directed
diagnostics involve the detection of the virus via recognition
elements (commonly specific antibodies) that capture exposed
proteins in the structure (viral antigens), such as the S (spike)
protein in coronaviruses, or the HA protein (hemagglutinin
glycoprotein) in influenza virus. Conventional approaches, such
as the enzyme-linked immunosorbent assays (ELISA) or
immunofluorescence staining, are used to identify the virus
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and provide qualitative or semiquantitative results with adequate
sensitivity. Although very specific, they require highly skilled
personnel for optimal accuracy, and they are time- and labor-
consuming.3,24−26 A few of them are also commercialized either
for the detection of a panel of respiratory viruses with its
benchtop instrument, such as mariPOC tests (via sandwich
immunoassay run in automatized mode), or for individual plate-
based kits, although they are not commonly used for routine
diagnosis.
Instead, rapid antigen diagnostic tests (RADTs) based on
immunochromatography (IC) or lateral flow assays (LFA) have
expanded widely, adapting the immunoassay concept to
disposable, inexpensive, fast (around 15 to 60 min turnaround
time), qualitative (yes/no), and point-of-care testing. The
RADTs are cellulose-membrane strip tests, commonly using a
sandwich assay. The sample containing the virus (or viral
antigens) is placed in the sample pad area, which flows by
capillarity to differentiated areas: first, a pad containing specific
labeled (fluorescent tag, gold nanoparticles, etc.) antibodies
against the antigens, which captures the analyte (if present).
When the sample gets to the detection line, the analyte−
antibody complex is captured by other immobilized specific
antibodies, forming a sandwich complex and revealing the
presence of the viral antigen in the sample. These tests are
commercially available for most common respiratory viruses
such as influenza A and B or the RSV.6 Some RADTs have also
been urgently developed and launched for COVID-19
diagnostics.18 For example, Coris BioConcept has launched a
dipstick rapid test (COVID-19 Ag Respi-Strip) with a claimed
specificity of around 98% but a sensitivity of about 60%; SD
Biosensor, with the Standard Q COVID-19 Ag test, reaches a
sensitivity of 84%. Despite the advantages for POC massive
testing, these tests have critical issues, such as the very limited
sensitivity (especially in adults)27 and a poor PPV (positive
predictive value), which is more evidently revealed when they
are compared with nucleic acid tests, whose levels of accuracy
and sensitivity are very high. The low reliability of these tests
might be in part due to the limited quality of biological material
employed for their development (both antibodies and antigens,
used for either the antibody production or the assay develop-
ment and validation), which essentially requires time for
optimization, and is especially manifest with a new, unknown
emerging virus.
Serological Assays. Serology assays are based on the
indirect identification of the virus infection, through the specific
detection of the antibodies generated by the infected host during
the immune response. Usually, this process starts a few days after
infection, and once the virus has been cleared from the organism,
the antibodies remain in the bloodstream, generally for several
years (although it depends on the disease and the pathogen).
This approach is useful for diagnostics (particularly in
retrospective diagnosis), but it is especially attractive for
surveillance and to perform epidemiological studies,28,29 to
estimate the prevalence, and to monitor the levels of antibodies
over time, which help assess the duration of the acquired
protection or immunity. Antibodies generated by the body often
target key antigenic determinants in the pathogen, for example,
the structural proteins of the virus. Thus, the detection
mechanism of this strategy involves the analysis of blood (or
serum) from the patient and the antibody detection through
their specific capture by those viral antigens.30−32
There are several enzyme immunoassay (ELISA) kits
available for the detection of serum antibodies to most common
respiratory viruses, such as adenoviruses, influenza A and B
viruses, parainfluenza, or RSV. These kits can provide more
reliable and quantifiable data and are meant to be used in central
laboratories with appropriate readers. However, the most
straightforward and most widely commercialized assays rely
on LFA tests, analogous to those for virus rapid detection in test-
strip format, with the viral antigens being adsorbed on the paper-
based pads. Most of them provide information on the type of
antibody detected (IgG and/or IgM), which may help
differentiate different stages of the infection (e.g., acute phase
or past infection). Due to the emergency situation, COVID-19
serology studies are currently intensively performed worldwide
for both diagnostics and pandemic monitoring purposes,33−35
and these tests are under development and commercialization.
Both microplate format immunoassays (ELISA) and rapid LFA
tests have been the main focus,8,18,36 although not with the
desired outcome in the case of rapid tests. Most of the
commercialized tests lack minimum sensitivity and reproduci-
bility to be reliable and accurate, partially due to the lack of
rigorous quality and accuracy controls before commercializa-
tion. Besides, LFA tests only provide qualitative information
(yes/no to the presence of antibodies). As the COVID-19
disease is not well-known yet, the immune response according to
the severity (asymptomatic, mild, or severe outcome) or the
duration of the acquired immunity, if any, requires a highly
reliable, sensitive, and ideally quantitative strategy, which
current LFA-based techniques are not providing.
Optical Biosensors as Potential Integrated Diagnostic
Approach. For respiratory virus infections, especially of
emergent viruses, which we are facing more often, a more
integral diagnostic approach that provides fast and quantitative
information is highly needed. Having a unique single platform
that can group all three diagnostic strategies discussed above,
combining the best features of all of them, represents an unmet
need that currently available technologies cannot provide.
Developing, implementing, and commercializing a device which
can deliver the specificity and accuracy of nucleic acid-based
detection, the convenience of fast detection of the virus directly
in the extracted sample, or the detection and quantification of
antibody titer directly in collected serum or blood, at the point-
of-care, with enough reproducibility, accuracy, and sensitivity, is
a very challenging task. Optical biosensors are at the forefront in
this singular race, as they provide outstanding characteristics as
excellent levels of sensitivity, robustness, and immunity to
electromagnetic interferences, miniaturization and integration
capabilities, and portability, among others.37,38 Therefore,
optical biosensors are excellent candidates to move the analysis
from centralized laboratories to the point-of-care.39,40 Optical
biosensors measure variations of the optical properties of the
propagated light (i.e., absorption, polarization, intensity, wave-
length, dispersion, or refractive index) when the interaction
between the receptor (antibody, nucleic acid sequences,
enzymes, proteins, etc.) and the target analyte takes place.
Among them, the ones founded on the evanescent field sensing
principle, such as the photonic and plasmonic biosensors,41−43
have already demonstrated their enormous potential as sensing
tools in a myriad of environmental, industrial, pharmaceutical,
and, especially, clinical scenarios.44−46 Evanescent wave optical
biosensors operate in a label-free configuration (no fluorescent,
colorimetric, enzymatic tag is needed), and their level of
sensitivity allows them to get rid of further amplification steps
that prolong and complicate the assay. They have the potential
to increase the multiplexing capability, facilitating the
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simultaneous detection of several targets, by having different
sensing channels within the same chip. As they rely on the
monitoring of changes occurring on the surface of the biosensor
chip, they can also be literally adapted to any kind of target (for
example, detection of the virus, nucleic acid sequences, or
antibodies; see Figure 1), as long as carefully selected receptors
are immobilized on the surface, to ensure the sensitivity and
specificity requirements for a given application.
Both plasmonic sensors, based on metallic transducers (thin
gold films or nanostructures), and silicon photonics, fabricated
by conventional microelectronics technology, are in continuous
progress to move from working laboratory prototypes to
compact, integrated versions that can be deployed outside the
lab, near to the patient. These devices have already been
successfully applied for the diagnosis of pathogens, both bacteria
and viruses, demonstrating their potential for this diagnostic
area.47,48 As discussed in the following sections, the technology
sensitivity and scalability, the selection of the receptors to target
the virus, and the appropriate biofunctionalization strategy on
the sensor surface are crucial aspects to consider for
implementing successful diagnostic biosensors.
■ NANOPHOTONIC BIOSENSORS: WORKING
PRINCIPLES AND TECHNOLOGIES
Most common nanophotonic transducers rely on nano-
plasmonics or silicon photonics technologies. The underlying
physics of these sensors have been widely studied and described
previously and can be explained on the basis of the evanescent
field sensing principle.40,42,49,50 In optics, an evanescent wave is
formed when light traveling in a medium undergoes total
internal reflection (TIR), generating a near-field enhancement
at the boundaries that penetrates in the surrounding dielectric
medium with a vanishing intensity. The evanescent field is
extremely sensitive to changes in the refractive index (RI) of the
medium, which are translated in more drastic changes of light
properties such as the intensity, phase, resonancemomentum, or
polarization. It is important to note that the intensity of the
evanescent field decays exponentially; therefore, the sensing
probe is restricted to the immediate vicinity of the transducer
surface and expanding up to a few tens of nanometers depending
on the transducer. In other words, when a biomolecular
interaction or binding occurs at the sensor surface within the
evanescent field, it can be directly monitored by interrogating
wavelength displacements, light intensity, or phase variations,
among others, in a real-time and label-free format with
impressive sensitivity.
Nanoplasmonic Biosensors. The Surface Plasmon Reso-
nance (SPR) system is the landmark of label-free nanophotonic
biosensors. The SPR biosensor generally employs a nanometer-
thin layer (40−50 nm) of gold as a transducer. An incident light
beam excites coherent oscillations of the metal conduction band
electrons (i.e., surface plasmon polariton) that propagates along
the interface metal-dielectric, generating an evanescent field that
can extend up to a few hundreds of nanometers (10−300 nm)
into the surrounding medium. When specific biorecognition
elements (e.g., antibodies or DNA strands) are immobilized
onto the gold surface, the selective capture and binding of the
target molecule induce a change of the RI and in the light
properties, which can be monitored and is directly proportional
to the concentration of the analyte in the sample (Figure 2a).
The RI limit of detection of SPR biosensors typically reaches
10−5−10−6 refractive index units (RIU), which commonly
relates to detection limits in the low nM or even pM level in
surface analyte detection. This analytical technique is consid-
ered mature nowadays, and its potential has been vastly
demonstrated by a myriad of applications in molecular biology
for the study of biomolecular interactions, in pharmaceutics for
the affinity and kinetics evaluation of drug candidates, and in
environmental and biomedical diagnostics for the detection and
quantification of specific substances (i.e., small molecules,
protein, nucleic acids, or pathogens) in different types of
samples (e.g., food, water, human bodily fluids, etc.).51−53 In the
past two decades, amid the rise of nanotechnology, plasmonic
biosensors have evolved to incorporate more sophisticated
nanostructures that can enhance the sensing performance and
improve miniaturization and integration capabilities. Nano-
patterned surfaces, such as arrays of nanoholes, nanodisks, or
nanorods, and more complex geometries like nanostars,
nanodimers, or oligomer assemblies, have emerged as
interesting alternatives to conventional SPR for the develop-
ment of ultrasensitive label-free biosensors as point-of-care
integrated devices (Figure 2b).39,43 Instead of propagating SPR,
these plasmonic nanostructures exhibit a localized resonance
(i.e., localized surface plasmon resonance, LSPR) that is
characterized by the higher confinement of the evanescent
field, with penetration depths around 10−50 nm, and by the
spectral tunability of the resonance. Theoretically, the LSPR
provides higher detection sensitivity, especially for relatively
small targets, given that the biomolecular interaction occurs
within the entire depth of the evanescent field. The evidence of
Figure 1. Biosensing strategies for virus infection diagnosis: (A)
detection of viral genomic material (i.e., DNA or RNA) by direct
hybridization to a DNA probe; (B) detection of intact virus entities by
antigen-specific recognition of antibodies; (C) detection of human
antibodies against the virus antigens (serology assay).
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this has been especially shown in Surface-Enhanced Raman
Spectroscopy (SERS) sensors, where the LSPR near-field is
exploited to largely intensify the Raman effect, providing
outstanding sensitivities that can even achieve single-molecule
detection.54 On the other hand, perhaps the most appealing
features of nanoplasmonic sensors rely on the capabilities for
spectral resonance design and more straightforward optical
configuration possibilities. While propagating SPR generally
requires complex light coupling schemes (e.g., prism-based
Kretschmann configuration), several LSPR sensing platforms
can work under normal light illumination, thereby simplifying
miniaturization and integration in small, portable, and user-
friendly devices. This capability also facilitates the development
of two-dimensional sensingmicroarrays for multiplexed analysis.
Besides, the design and modeling of the nanostructured
architecture enable the rational definition of the spectral peak
position at convenient wavelengths, so allowing for the use of
affordable and widely available light sources, like light-emitting
diodes (LEDs).43
Nanoplasmonic biosensor technologies, both SPR and LSPR
based, are nowadays available and commercialized worldwide.
In the case of SPR, large companies like GE Healthcare
(Biacore), Horiba, or Bruker, among others, deliver high-quality
benchtop systems that are routinely used in research laboratories
or the pharmaceutic industry. A few manufacturers also
commercialize LSPR-based instruments, such as Nicoya Life
Sciences or LSPR AG. However, despite the advanced
technological and analytical capabilities offered by these
instruments, their adoption in the clinical diagnostics field for
a given application is still very limited. This can be related to the
need for a robust, reproducible sensor surface biofunctionaliza-
tion protocol, which usually must be optimized for each analyte,
and the difficulties of analyzing complex samples like biological
fluids. Furthermore, the achievement of truly POC nano-
plasmonic biosensors needs to incorporate and improve
microfluidic systems that minimize or automatize sample
processing, and user-friendly readouts that can be directly
interpreted by nonspecialized users.
Silicon Photonics Biosensors. Despite the predominance
of nanoplasmonic biosensors as a reference in label-free optical
sensing, silicon photonics technologies have arisen as leading
platforms in terms of sensitivity and integration capabilities.
Silicon photonics biosensors are based on integrated optical
waveguides fabricated on Si, Si3N4, SiON, or SiO2 materials.
Light travels along these microscopic waveguides under a TIR
regime, generating an evanescent electromagnetic field with
penetration depths between 100 and 900 nm that is used as
biosensing probe. The vast knowledge and robustness of silicon-
based technologies, including conventional microelectronics
fabrication and characterization procedures, together with the
low power consumption and the capability to incorporate all the
functions (chemical, optical, microfluidics, and electronics) in
one single platform, make these systems ideal for lab-on-a-chip
implementation and use as point-of-care diagnostics.40,41
Most common Si photonics sensors are interferometers, ring
resonators, and photonic crystals, although other technologies
have also been developed, such as grating-coupled waveguides,
silicon wires, slot waveguides, or optomechanical sensors,
among others.41 Interferometric biosensors, like the Mach−
Zehnder (MZ), Young, or bimodal waveguide (BiMW)
interferometers, stand out for their broad dynamic range and
exceptional sensitivity, reaching detection limits in the range of
10−7−10−8 RIU.44,50 Figure 2c illustrates the working principle
of a MZ interferometric sensor. Briefly, an input waveguide is
split into two arms (sensing and reference arms) that, after
certain distance, are recombined into a single output.
Biomolecular interactions occurring at the sensing arm within
the evanescent field induce a phase difference with the light
Figure 2. Schematic illustrations of the main label-free nanophotonic biosensor technologies: (A) Surface Plasmon Resonance (SPR) biosensor in
Kretschmann configuration; (B) Localized Surface Plasmon Resonance (LSPR) biosensor based on gold nanodisks; (C) Mach−Zehnder
interferometric (MZI) biosensor; and (D) ring resonator biosensor.
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traveling along the reference arm. When recombined, the
generated interference provides the direct, label-free, and real-
time signal directly proportional to the analyte concentration. A
variety of interferometric biosensors with different designs have
been developed and applied for clinical diagnosis purposes,
showing detection of small molecules,44 protein biomarkers or
glycolipids,55 nucleic acids in the aM−fM range,56 or just a few
pathogenic entities (e.g., 4−10 bacteria/mL).57
Ring resonators, meanwhile, have attracted attention due to
their unique potential for integration into high-throughput
arrays for multiplexed analysis,38,58 with highly efficient and
scalable fabrication. Ring resonator transducers consist of
circular waveguides that generate whispering-gallery modes
(WGM) upon light coupling to the loop, enhancing the
evanescent field intensity (Figure 2d). Detection is performed
by interrogating the WGM spectral resonance position. The
multiplexing capabilities of ring-resonator arrays have been
demonstrated for the simultaneous detection of panels of
relevant diagnostic biomarkers, like cancer-related proteins or
microRNAs.38
Finally, photonic crystals also hold promising potential for
point-of-care biosensors due to their cost-effective fabrication
and high-throughput possibilities.59,60 Photonic crystals are
well-defined nanostructures with periodically repeated layers of
different refractive index. The lattice structure generates
photonic bandgaps, highly dependent on the dielectric refractive
index. These sensors have also been applied for biological assays
achieving moderate sensitivities, compared to their silicon
photonics counterparts (in the nM−pM range), but they would
greatly benefit from an easy and low-cost mass production of
disposable photonic sensor chips.
Silicon photonic technologies have also started recently to hit
the biosensors market with some successful systems like the ring
resonator-based platform supplied from Genalyte. However,
they suffer from the same shortcomings as nanoplasmonic
technologies in terms of surface biofunctionalization and
integration in automated and user-friendly lab-on-a-chip devices
for their implementation in the clinical field. Extended
discussion in this regard is provided in the following sections
of this review.
■ BIORECEPTORS AND SENSOR SURFACE
BIOFUNCTIONALIZATION
The performance and, especially, the sensitivity and selectivity of
surface-based nanophotonic transducers will ultimately depend
on the most appropriate biorecognition element that binds
specifically the target analyte, and on the conditions for the
coating of this receptor. As for any application to be developed,
bioreceptors are selected according the approach for detection
of the target. In the case of viral infection diagnosis, considering
the three main strategies described before, these would be DNA
capture probes for nucleic acid detection, specific receptors like
antibodies for antigen-directed virus capture, or viral antigens
for serological tests. However, many variants and innovative
bioreceptor elements have been developed to enhance the
sensing performances (see Table 1). It is important to note
though that the access to high-quality and well-characterized
biological reagents, especially antigens and antibodies, can be a
significant problem, in particular at the start of an outbreak from
a new pathogen, like the SARS-CoV-2. This inherently delays
the development of reliable sensor technologies as well as other
diagnostic approaches, such as the RADTs, as discussed before.
For the case of genomic hybridization assays, oligonucleotide
capture probes are designed and synthesized with the
complementary sequence to the specific viral target region.
Primarily, the specificity will depend on the sequence selection
of the probe and, second, on the hybridization conditions,
mainly buffer composition and temperature. Aspects to be
considered when designing the probe will be the pair length and
the nucleotide sequence, because they will affect the binding
energy and stability of the complex. In addition, especially in
RNA detection, secondary structures around the targeted zone
might hinder the binding to the probe, and then, it is essential to
select regions where these folds are not formed.61 For some
cases, where the biosensor sensitivity is not enough, the use of
tagged hairpin probes or the hybridization of additional labeled
sequences has been prevalent as amplification steps. For
instance, stem-loop oligos tagged with signal amplification
Table 1. Bioreceptors Applied for Virus Diagnosis
genomic detection
receptor advantages limitations
DNA probes Stability and specificity Not sensitive enough in









Lower limits of detection Additional steps




Antibodies Robust and well established Animal requirement
Wide range of ligands High production costs
High binding affinities and
selectivity






No animal requirement in the
production
Need to know the sequence,
or find binding regions
through phage display





Aptamers Possibility of engineering SELEX procedure is long








Need of prior studies of
glycan affinities to viruses
serological assay
receptor advantages limitations
Viral lysates Easy to produce Not homogeneous receptor
layers










Need to identify the gene
sequence
Relatively easy to produce Cross-reactivity with strains





viruses of the same family
Need to know sequence,
structure, and identify the
domain
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compounds (e.g., SERS reporters) have been used to improve
the detection limit in the analysis of different human viruses.62
For antigen-directed virus detection, most common bio-
receptors are monoclonal antibodies, which can be produced to
target specific viral antigens and have been extensively used in
biosensor development. In the past decades, smaller recombi-
nant antibody fragments and engineered variants have become
advantageous alternatives.63 These peptides can be selected by
phage display, which allows screening of clone libraries of
recombinant phages expressing on their surface the binding
regions of antibodies and proteins. The selected ones can be
identified and produced synthetically or expressed in bacteria,
with fewer requirements than the production of antibodies in
hybridomas or mammal cells. As an alternative, aptamers, which
are short DNA/RNA sequences that also bind with high affinity
and specificity to target molecules, have also been proposed for
the detection of viral antigens, showing sensitivities comparable
to monoclonal antibodies.64−66 Main advantages are related to
the simpler production and possibility to introduce any desired
functionality for surface immobilization. However, the selection
procedure is not yet well established to be massively
commercialized and employed with sufficient robustness. At
present, many aptamers have been isolated for the recognition of
human viruses,67,68 and particularly for respiratory viruses; most
of them have been designed to detect distinct strains of
influenza.69−71 Finally, cell receptors have also been proposed
for direct virus detection, as the case of glycans from the host
cells. Surface receptor glycans have been, in fact, widely used in
conjunction with biosensors for the detection of different strains
of influenza.72−74 Moreover, the combination of glycoprotein
receptors and antibodies has improved the specificity of the
sensor to certain viral strains.75
For serological assays, the bioreceptors essentially consist of
viral antigens, the same that cause the host immunogenic
reaction.76,77 The first serological tests employed whole virus
lysates for the recognition of the host antibodies, resulting in test
variability and false positives due to the presence of host proteins
in the virions.78 Since then, advances in cloning, genetic
engineering, and the establishment of robust expression systems
make possible the use of recombinant viral antigens instead.
Once the genome of different viral strains is available,
recombinant proteins are produced at large scale in bioreactors,
facilitating the production of homogeneous reactive layers. By
using cloned proteins, large amounts of purified antigens can be
produced and isolated with less cost in addition to reducing the
risk of infection.79 In some cases, the whole viral protein is not
necessary since only a part of the protein causes most of the
immunogenic reaction in the individuals. Then, the production
of this small region (which can be a short peptide) may be
enough, simplifying the process. Compared to the whole
recombinant protein, these shorter peptides are designed to
include nonconservative regions, so they have fewer cross-
reactions with sera raised against similar viral infections,80,81
thus increasing the specificity. These short peptides are
habitually conjugated to larger proteins, known as carrier
proteins, to increase stability and facilitate surface immobiliza-
tion.82,83
Besides the bioreceptor selection and its quality, a critical
factor for the biosensor performance is the appropriate surface
functionalization and its immobilization, taking into account
orientation, stability, reproducibility, and prevention of non-
specific adsorption of matrix components of the biological
samples. The bioreceptor immobilization to the transducer
surface (e.g., gold or silicon derivatives) can be done in different
ways: by direct chemical or physical adsorption, by covalent
linking to a chemical matrix, and through affinity binding to
certain molecules. Physical adsorption through electrostatic and
hydrophobic interactions is not recommended, as it can lead to
biomolecule denaturation, and very low stability and reprodu-
cibility. Certain biomolecules, however, can be directly
chemisorbed to the surface, for example, via thiol (-SH) binding
to gold.84 This is widely employed for oligonucleotide probe
functionalization (DNA probes or aptamers). It can also be used
with proteins by the cysteine residues, although in some cases, it
can lead to the wrong orientation of the molecules.85
Covalent immobilization involves the chemical modification
of the transducer surface to generate a functional chemical
matrix (e.g., self-assembled monolayers, SAMs), where bio-
molecules can be covalently bound. Compared to the previous
approaches, it offers some advantages: a more uniform and
controlled surface coverage, possibility for long-term storage,
and sensor reusability. The SAMs are created by distinct
compounds depending on the transducer material, e.g.,
alkanethiol molecules for gold (which involves very well
established and reproducible procedures) and alkosysilanes for
Si-based sensors.85,86 The silanization procedure, although also
widely used, is relatively complex, and many factors influence its
reproducibility, such as the silane concentration, solvents
employed, reaction times, or temperature. The molecules that
comprise either type of SAMs can be engineered to have
different lengths and terminal groups that allow the grafting of
the probes. The most common SAMs terminations are amine
(NH2), thiol (SH), carboxyl (COOH), and epoxy (COC)
functionalities that can be cross-linked with native or engineered
functional groups in the biomolecules. Given the broad range of
linkers used depending on terminal groups, we invite the reader
to check other reviews and chapters for a more in-depth
classification of compounds, protocols, advantages, and draw-
backs.85,87−89 Finally, affinity-based immobilization strategies
are also commonly employed for bioreceptor immobilization,
with streptavidin−biotin coupling the more employed.90 This
strategy involves streptavidin coverage of the surface by
adsorption or covalent linkage and the addition of the
biotinylated receptor. This approach requires the labeling of
the receptor with biotin groups but provides a highly stable and
specific bond. Another affinity-based immobilization strategy
widely used, especially for antibodies, involves the use of Protein
A or G, which binds with high affinity to the Fc region of
antibodies. This methodology provides an efficient strategy to
orientate the antibodies to the outer medium, leaving more
exposed the regions responsible for the specific binding.91
Lastly, there are two other critical aspects to consider: (i)
ensuring adequate bioreceptor density, minimizing possible
steric hindrance effects, and (ii) avoiding nonspecific
interactions on the sensor surface. In the first case, it is necessary
to study the effect of combining mixed SAMs (with reactive and
nonreactive) groups, which help space out the distribution of
receptors (particularly important if they are large molecules, like
are bacteria or viruses) or also spacers that move away the
receptor from the sensor surface (i.e., increasing their
accessibility). On the other hand, nonspecific interactions,
often referred to as “fouling”, are a critical issue when analyzing
clinical samples such as saliva, sputum, urine, serum, or blood, as
they can induce misleading signals (i.e., false positives resultant
of binding to the sensor surface and change in the refractive
index) and might also hinder the recognition of low-
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concentration analytes.92 There is extended research devoted to
study the factors influencing these interactions and to develop
strategies to counteract them. The antifouling strategies involve
the use of compounds that prevent the adsorption of other
compounds while preserving the affinity and sensitivity of the
recognition elements. These coatings have been able to avoid
the fouling attachment by the creation of hydration layers and
electrostatic and steric repulsions.93 Materials that have shown
Table 2. Nanophotonic Biosensors Applied for Respiratory Virus Diagnosis
genomic detection
biosensor
technique virus receptor target sample sensitivity ref
LSPR SARS-CoV-2 DNA probe RNA Buffer 0.2 pM 98
Microring
Resonators





SPR Influenza A and B, H1N1, RSV, parainfluenza, adenovirus,
and SARS-CoV
DNA probe RNA Buffer 1−5 nM 100
SERS High-pathogenic avian influenza (HPAI) Raman-tag hairpin DNA
probe
RNA Buffer 2−3 aM 62
intact virus detection
biosensor technique virus receptor target sample sensitivity ref
SPR Avian influenza H6N1 Antibodies H6N1 virion Buffer 5 × 106 EID50/mL 103
SPR Avian influenza H7N9 Antibodies HA protein Buffer 200 copies/mL 104
SPR Enterovirus 71 Antibodies VP1 protein Culture media 67 virus particles/mL 105
SPR Avian influenza H5N1 Aptamer HA protein Poultry swab samples 0.128 HAU/mL 70
SPR Avian influenza H5Nx Aptamer HA protein Buffer 200 EID50/mL 69
Waveguide interferometer High-pathogenic avian influenza (HPAI) Antibodies HA protein Buffer 0.0005 HAU/mL 106
Silica Inverse Opal Avian influenza H1N1 Antibodies HA protein Buffer 103 PFU/mL 107
Photonic Crystal Avian influenza H1N1 Antibodies HA protein Saliva samples 1 ng/mL 108
Mach−Zehnder Avian influenza H1N1 Antibodies HA protein Buffer 1010 virus particles 109
Figure 3. (A) Example of nanophotonic biosensor applied for COVID-19 diagnosis via genomic detection of SARS-CoV-2. Reprinted (adapted) with
permission from ref 98. Copyright (2020) American Chemical Society. (B) Example of nanophotonic biosensor applied for direct detection of intact
viruses (influenza). Reprinted (adapted) with permission from ref 104. Copyright (2018) American Chemical Society. (C) Example of smartphone-
integrated optical biosensor. Reprinted (adapted) with permission from ref 130. Copyright (2017) Elsevier. (D) Example of microfluidics-integrated
optical biosensor. Reprinted (adapted) with permission from ref 134. Copyright (2014). American Chemical Society. Please refer to original articles
for reprint.
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excellent antifouling properties include polyethylene glycol
(PEG), zwitterionic polymers, polysaccharides such as dextran,
and proteins like bovine serum albumin (BSA).94
■ NANOPHOTONIC BIOSENSORS FOR VIRUS
DETECTION
The potential and versatility of label-free nanophotonic
biosensors for medical diagnostics have been widely demon-
strated, including virus detection and identification, especially
for the human immunodeficiency virus (HIV) and the hepatitis
B virus.47,94−97 Hereby, we provide a brief review of the latest
developments in nanophotonic biosensors for respiratory virus
infection diagnosis based on the three main assay strategies
described above.
Nanophotonic Biosensors for Viral Genomic Analysis.
Detection of specific genomic sequences with label-free
photonic biosensors is usually carried out through rapid
hybridization assays. If the biosensor is sensitive enough, direct
detection from the sample might be possible, without
preamplification steps (PCR-free), although it still requires
extraction and fragmentation procedures to be performed before
the biosensing assay.
Due to the intricate bioassay design and procedure, only a few
biosensors have been developed for the genomic assay of
respiratory viruses (see Table 2). At the time of writing this
review, at least one nanoplasmonic biosensor has been reported
for the detection of the SARS-CoV-2 virus. Qiu et al. have
developed a dual-mode nanoplasmonic system, consisting of
two-dimensional gold nanoislands, that combines plasmonic
photothermal effect and LSPR sensing transduction (Figure
3a).98 The sensor is functionalized with a DNA probe of a
complementary sequence to the RdRp RNA gene of the
COVID-19 virus. The specific nucleic acid hybridization,
enhanced by the thermoplasmonic heat generated at the
nanoislands, is detected as a LSPR phase shift that can be
monitored in real-time. They achieved a limit of detection
around 0.2 pM for the target RNA sequence, which could be
translated into approximately 2× 104 copies of the SARS-CoV-2
virus, showing good potential for COVID-19 diagnostics.
Previous studies have also addressed the genomic analysis of
viral infections. Koo et al., for example, developed a label-free
biosensor using silicon microring resonators for the diagnosis of
respiratory viral infections. They performed an isothermal RNA
amplification coupled to the hybridization biosensing assay for
the detection, all within 20 min.99 The biosensor was applied for
the analysis of nasopharyngeal samples from patients infected
with influenza A and B, human coronavirus OC43/229E, and
RSV A and B, respectively. The limit of detection was found
close to 2.5 × 101 copies/reaction and clinical sensitivities
between 85% and 100%, although specificity was low for some
viruses (40−60% for hCoV) probably due to the lack of enough
samples. This biosensor exhibited a reliability comparable to
that of conventional RT-PCR, reducing the analysis time to a
few minutes and avoiding additional fluorescence or electro-
phoresis-based detection methods. With a similar aim, Shi et al.
reported an SPR biosensor for multiplexed RNA detection of
several respiratory viruses: influenza A and B, H1N1, RSV,
parainfluenza virus, adenovirus, and SARS coronavirus simulta-
neously.100 However, a previous PCR amplification of the target
genetic material plus a secondary streptavidin-amplification step
after hybridization were required. Overall, sensitivities achieved
were in the range of 1−5 nM. Other nanoplasmonic approaches
like SERS have also been applied for respiratory virus genomic
analysis. For example, Pang et al. developed a SERS sensor
combined with a molecular sentinel for the detection of the
avian influenza virus. They reached detection limits around 2−3
aM, allowing a PCR-free analysis method.62
As major assets compared to standard RT-PCR technique for
viral genomic analysis, these nanophotonic biosensors account
with the direct and label-free capabilities that reduce total
turnaround analysis time from several hours (4 to 6) to less than
30 min. Potential applications of these technologies for the
COVID-19 pandemic and possible future outbreaks could
signify the realization of truly reliable massive testing and
screening. By targeting appropriate gene sequences and
providing ultrasensitive analysis, the genomic biosensing assays
can provide highly accurate and specific detection of the virus,
even when viral load is low. Furthermore, by establishing
multiplexed genomic analyses, it could be possible to identify
different types of viruses or strains in one single assay.
Nanophotonic Biosensors for Antigen-Directed Virus
Detection. The first works for intact virus detection with label-
free optical biosensors were reported by Schofield andDimmock
around 25 years ago.101 They employed an SPR biosensor to
determine the affinities of different antibodies and Fab
fragments for influenza A viruses by monitoring the capture of
whole virions. Since then, many researchers have been
developing new biosensor assays for rapid virus detection and
quantification with plasmonic and photonic technologies (see
Table 2). The vast majority of the work in respiratory virus
diagnosis targets influenza viruses and the different subtypes.102
In recent publications, for example, Zhao et al. reported an
optical SPR fiber sensor for the detection of avian influenza
virus.103 With a compact and low-cost system, they were able to
detect around 5 × 105 EID50 in 100 μL sample within 10 min.
Chang et al. also employed an SPR biosensor for avian influenza
detection with a newly generated antibody (Figure 3b).104 They
reached a detection limit of around 200 copies/mL, which
resulted in 20-fold improved sensitivity compared to analogous
ELISA tests, and better than conventional RT-PCR and rapid
diagnostic tests. Likewise, Prabowo et al. proposed a portable
SPR biosensor for the rapid quantification of enterovirus
antibodies targeting the VP1 membrane protein.105 The SPR
system showed a detection limit of 67 virus particles per
milliliter. Besides antibodies, aptamers have also been applied
for avian influenza virus detection. Bai et al. developed an SPR
aptasensor with detection sensitivities around 105.70 A more
exhaustive study was reported by Nguyen et al., including the
selection of aptamer pairs to develop a sandwich-type SPR assay
for avian influenza virus detection.69 In this assay, they reached
sensitivities around 200 EID50/mL.
Apart from plasmonics, other nanophotonic sensors have also
been applied for direct virus detection. Xu et al. developed a
waveguide-based interferometric biosensor for the direct
detection of influenza viruses.106 They tested different
monoclonal and polyclonal antibodies targeting the HA protein
of the membrane of influenza viruses. Their biosensor
immunoassay reached outstanding sensitivities, with a detection
limit of 0.0005 HAU. Lee et al. fabricated a label-free optical
sensor based on three-dimensional inverse opal silica nano-
structures.107 Their application for direct avian influenza virus
detection by antibody capturing rendered sensitivities in the
range of 103−105 PFUs (plaque forming units). Endo et al.
developed a flexible two-dimensional photonic crystal biosensor
employing antibodies targeting avian influenza virus HA
protein.108 They reached a limit of detection of 1 ng/mL for
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direct measurement in human saliva samples. Finally, Sakamoto
et al. employed a Mach−Zehnder interferometer for avian
influenza diagnostics.109 They only tested the technology for the
detection of 1010 virus particles that showed a clear signal
response in comparison with the negative control.
The availability of sensitive and reliable intact virus detection
tests for SARS-CoV-2 could transform the outbreak status,
management, and progression. The implementation of bio-
sensors for rapid screening of the population and immediate
detection of COVID-19 would allow more efficient patient
isolation and spread control. Nanophotonic biosensors have
demonstrated superior sensitivity and robustness compared to
LFA tests, plus they offer quantitative results in approximately
the same turnaround assay times. Ongoing research is focusing
on developing and applying these valuable technologies for
direct and rapid diagnostics, and especially for the point-of-care
testing of coronavirus infection. A good example is one of the
first and largest research projects funded by the European
Commission to tackle the COVID-19 pandemics (i.e., CoNVat
project), which will employ a silicon interferometric sensor for
intact virus detection in nasopharyngeal and saliva samples.110
Besides, a few reports have been uploaded in non-peer-reviewed
repositories showing proof-of-concept studies. For example,
Ahmadivand et al. have developed a plasmonic metasurface for
sensing the S protein at the femtomolar level.111 On the other
hand, Zhang et al. employed silver nanorod SERS sensors for
ultrafast detection of viral antigens (RBD). The technology has
been applied for water monitoring but could also be adapted for
diagnostics.112
Nanophotonic Biosensors for Serology and Immunol-
ogy Assays. Although not considered a primary diagnosis
strategy, serology and immunology assays have a strong
relevance in an infection disease prevalence study and the
design and assessment of vaccines and other therapeutics.
Optical label-free biosensors offer a unique technique to
facilitate, accelerate, and improve the routine pharmaceutical
and biomedical analysis.
Serology biosensing assays are relatively easy to implement, as
they essentially consist of direct quantification of antibodies
through binding to their corresponding antigen immobilized on
the sensor surface. Scarcely any articles have been recently
published for the development and validation of such serological
biosensors for respiratory viruses.113,114 However, the emer-
gence of SARS-CoV-2 and the urgent need for massive testing
has promoted the application of nanophotonic sensors for
COVID-19 serology with diagnosis and monitoring purposes.
Very recently, Shaw et al. have published a clinical evaluation
study of a nanoplasmonic technology for quantitative detection
of SARS-CoV-2 antibodies in different disease stages.115 Other
examples can be found in repositories. Abdelhadi et al. have also
developed a SPR bioassay for SARS-CoV-2 antibody testing,116
and Kulp et al. demonstrate the utility of SPR biosensors for
rapid antibody neutralization assays, studying recognition of the
ACE2 receptor.117
On the other hand, many research works in vaccine
development and evaluation employ plasmonic and photonic
biosensors for characterization and evaluation procedures. For
example, Fuentes et al. characterized the affinity and kinetics of
antibodies against RSV generated during vaccine development, a
key step in preclinical evaluation.118 Marsh et al. employed a
SPR system to assess the susceptibility of RSV to antifusion
protein antibodies,119 and Gauger et al. also used it for
evaluation of live attenuated influenza A virus vaccine.120 On
the other hand, Zhang et al. developed a novel arrayed imaging
reflectometry platform for the high-throughput study of the
serologic antigenicity of influenza viruses.121
It is important to note as well that nanophotonic biosensors
have shown exceptional utility in different virology and
immunology studies. Nilsson et al., for instance, published an
SPR biosensor for quantification of influenza virus HA protein
based on an inhibition assay.122 They immobilized the HA
proteins for different virus subtypes on the sensor surface and
quantified the levels of free specific antibodies in the sample,
after incubation with the infected sample. The limit of detection
was around 0.5 μg/mL, but they were able to identify the
different avian influenza virus subtypes and strains in serum
samples. Negri et al. used label-free SERS sensors for the
detection of viral nucleoprotein binding to an anti-influenza
aptamer.71 Although they did not reach a high sensitivity (1 μg/
mL), they could demonstrate specific detection of the influenza
nucleoprotein challenged to other respiratory viruses and
biological samples. On the other hand, Vidic et al. used an
SPR biosensor to identify and characterize a novel complex
between the nucleoprotein and the RNA polymerase of the
influenza A virus.123 This molecular complex has a role in the
final steps of transcription and replication of the virus, so it could
be a target for therapeutics. Xiong et al. applied biolayer
interferometry technology to measure the binding affinity of
human and influenza viruses to their cell receptors.124
In the coronavirus area, some studies have also been
performed with optical biosensors. After the last coronavirus
outbreaks (SARS and MERS), researchers have continued
studying and characterizing the virus structures and searching
for potential drugs and therapeutic agents. Huang et al., for
example, studied the evolution of the receptor-binding domain
(RBD) of the Spike protein of β-coronavirus and its interaction
with cell receptors, employing an SPR platform to characterize
the affinity and kinetics of the interaction.125 Likewise, Park et al.
evaluated different polyphenols as coronavirus protease
inhibitors with an SPR biosensor.126 They could select one of
these molecules as a promising candidate for developing
anticoronaviral agents.
The use of plasmonic and photonic biosensors in serology and
immunology studies has undoubtedly benefited the pharma-
ceutical industry and biomedical research. It could soon replace
long and tedious ELISA, offering a faster, simpler, and even
cheaper technique. For the COVID-19 case, serological analyses
have become crucial not only as a complementary diagnosis but
also for pandemics management and epidemiology studies. It is
now essential to perform massive tests for the whole population
to understand the incidence andmortality of the disease, and the
effects on human health and immunity. For the development
and evaluation of new vaccines or other therapies (e.g.,
hyperimmune serum treatments), it is crucial to accurately
study the generation and kinetics of sera antibodies, and
optimally in a quantitative and highly specific way. For that,
label-free nanophotonic biosensors are promising and realistic
solutions.
■ FUTURE PERSPECTIVES
Nanophotonic biosensors have demonstrated their detection
performance and capabilities for clinical diagnostics, including
discrete microorganisms such as micrometer-sized bacteria and
small viruses on the nanometer scale. The detection of
pathogens that tackle the drawbacks of current methodologies
is possible with the high levels of sensitivity this technology can
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reach. They can be used for the detection of antibodies in serum,
the detection of DNA and RNA fragments with excellent
performance, avoiding amplification, and even for the detection
of whole viruses, which shows the versatility to implement such
tools in the diagnosis of respiratory viruses such as SARS-CoV-2.
However, there is still much effort to be done, especially on
two fronts. First, to systematically perform rigorous clinical
validation of each individually optimized assay to fully assess the
reliability and robustness of the detection strategy. This is not
always provided as it involves the evaluation of a high number of
real samples to determine specificity and sensitivity statistics
parameters. Second and most importantly, we need a strong
push to move the technology from laboratory prototypes,
commonly installed in a controlled and robust environment, to
decentralized settings. This step involves the design of all-
integrated, autonomous, compact devices, incorporating optical
elements that facilitate both the reduction in size and in cost,
while retaining the performance achieved in laboratory versions,
to further pursue viable commercialization. In this sense, highly
advanced smartphone technology offers excellent and promising
platforms to design point-of-care versions (Figure 3c).127−130
For example, an optical interface based on complementary
metal-oxide semiconductor (CMOS) technology in the phone
cameras for readout, in combination with customized software
implemented via smartphone applications, can be used for
different optical detection approaches, from labeled approaches
(like colorimetry and fluorescence) to label-free detection,
through imaging readout or spectrummonitoring.131 Additional
components such as external light sources, like affordable LEDs
or broadband lights, collimators, or polarizers, can be included in
an adapted miniaturized design, involving also compatible and
suitable customized polymer shell or housing to merge with the
cell phone. More examples are appearing trying to combine
smartphone technology with plasmonic biosensors,132,133
although the performance is still undermined compared with
robust laboratory versions and they have been tested with model
biosensing systems or with limited analytical characterization.
Microfluidics also play a crucial role to provide disposable,
stable over time, easy-to-manipulate cartridges incorporating the
sensor chip with the specific biofunctionality for each detection
assay.135−137 In the case of airborne respiratory viruses, like
SARS-CoV-2, it will be essential to integrate such a cartridge
with additional sections that include sample preprocessing steps
before the final detection.138 Some of these steps might include
extraction of the viral genome from the clinical samples,139
separation of plasma, or serum from blood134,140−142 whose
direct measurement is exceptionally challenging with optical
biosensors, or even more appealing, oral samples pre-treatment
(nasopharyngeal swabs, saliva, sputum, etc.).143 In the case of
oral samples, viral load is expected to be high, and minimum
manipulation would facilitate the prevention of healthcare staff
infection as well as further expansion of the device use outside of
biosafety settings (e.g., primary care centers). There are plenty
of examples of microfluidics that perform filtration, extraction,
and centrifugation for preconcentration, and more complex
processes such as nucleic acid amplification. However, they are
commonly coupled colorimetric or electrochemical detections
and it is rarely reported for label-free optical biosensors. Some
interesting examples have already been proposed merging
microfluidics integration and nanophotonic biosensors (Figure
3d). For example, an individual polymeric cartridge with an
interferometric photonic chip that can be directly inserted in the
POC device, which has been validated for the pump-free direct
detection of tuberculosis in urine samples.55 Using automated
pneumatic-valve based microfluidics144−146 or digital micro-
fluidics147,148 instead of conventional microchannel-based
fluidic chips represents an emerging trend to be used with
silicon photonics given its potential to be integrated in
miniaturized design and its versatility to transport and mix
very small volumes with high precision, thus being very attractive
for multiplexed automated analysis. However, scarce examples
are found in the literature149 and not tested further with
biosensors. Despite the excellent biosensing performance of
nanophotonic biosensors, there is still a long road ahead in
several technological aspects to achieve fully operative silicon
and plasmonic devices for clinical diagnosis. The current
emergency situation, which has revealed the shortage of really
effective diagnostic techniques, may represent an inflection
point to push further the research and investment in optical
biosensors toward such levels of integration necessary to
successfully hit the market.
■ SUMMARY AND CONCLUSIONS
The outbreak of COVID-19 has dramatically exposed the urgent
need to upgrade the clinical diagnostics to implement new
technologies for POC testing with sufficient accuracy and
reliability. Nanophotonic biosensors have demonstrated in
academic settings the capabilities for such endeavor, offering a
unique potential to combine rapid virus detection and
identification, genomic analysis, and even serological assays in
one integrated platform. Key factors for the successful
implementation of label-free nanophotonic biosensors in virus
infection diagnosis are essentially the selection of appropriate
and high-quality bioreceptors, which confer enough sensitivity
and selectivity, together with a robust surface biofunctionaliza-
tion. The rational design and optimization of label-free
nanophotonic biosensors can provide direct detection of intact
virus entities or specific genomic identification directly from a
human sample with outstanding sensitivities (few copies per
milliliter). Further, the simplicity and efficiency for routine and
fast serological analysis could significantly contribute to
epidemiology studies or vaccine development. Henceforth,
research in nanophotonic technologies for diagnostic biosensors
should move a step forward to prove their capabilities in the
clinical field and provide fully operative point-of-care devices for
rapid, accurate, and massive infection diagnosis.
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■ VOCABULARY
Biosensor: an analytical device that integrates a biological
receptor (e.g., antibody, DNA probe, enzyme) in close contact
with a transducer (optical, electrochemical or mechanical).
Specific recognition events between the bioreceptor and the
analyte of interest produces physicochemical changes in the
transducer that are transformed into readable and quantifiable
signals; Nanophotonics: area of research that studies the
behavior of light and light-matter interactions at the nanoscale.
It includes research in physics, optical and electrical engineering,
and materials sciences, and it can be applied to multiple fields,
such as biology and biomedicine, energy, or telecommunica-
tions; Microfluidics: area of research that focuses on the
behavior and manipulation of fluids at the micrometer scale.
Microfluidic systems enable precise control and distribution of
fluids at very low volumes (from μL to fL); Surface
biofunctionalization: a series of procedures, usually based on
(bio)chemical processes, to incorporate or anchor a biological
element to a surface to provide specific functionality, e.g. analyte
recognition or capture; Virus: submicroscopic biological entity
that infects and replicates inside living cells of an organism, often
with pathogenic consequences; Antibody: also known as
immunoglobulin is a blood-circulating protein produced by
the immune system of an organism to recognize and neutralize
specific antigenic molecules or pathogens; Serology: analysis
and study of the blood serum composition for diagnostic
purposes, especially with regard to the identification of immune
system response (i.e., antibody production) to pathogenic
agents or other antigenic substances
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(47) Saylan, Y.; Erdem, Ö.; Ünal, S.; Denizli, A. An Alternative
Medical Diagnosis Method: Biosensors for Virus Detection. Biosensors
2019, 9 (2), 65.
(48) Daaboul, G. G.; Lopez, C. A.; Yurt, A.; Goldberg, B. B.; Connor,
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